These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35654163)

  • 21. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LDL-cholesterol change and goal attainment following statin intensity titration among Asians in primary care: a retrospective cohort study.
    Fang HSA; Gao Q; Lee ML; Hsu W; Tan NC
    Lipids Health Dis; 2021 Jan; 20(1):2. PubMed ID: 33407522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care.
    Marquina C; Talic S; Zomer E; Vargas-Torres S; Petrova M; Wolfe R; Abushanab D; Lybrand S; Thomson D; Stratton G; Ofori-Asenso R; Liew D; Ademi Z
    J Clin Lipidol; 2022; 16(4):498-507. PubMed ID: 35606299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
    Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
    Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II.
    Buddhari W; Uerojanaungkul P; Sriratanasathavorn C; Sukonthasarn A; Ambegaonkar B; Brudi P; Horack M; Lautsch D; Vyas A; Gitt AK
    Heart Lung Circ; 2020 Mar; 29(3):405-413. PubMed ID: 31006593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
    Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
    Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
    Simpson RJ; Tunceli K; Ramey DR; Neff DR; Kern DM; Hsieh HM; Wertz DA; Stephenson JJ; Marrett E; Tomassini JE; Jacobson TA
    J Clin Lipidol; 2013; 7(5):399-407. PubMed ID: 24079280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany.
    Waßmuth S; Rohe K; Noack F; Noutsias M; Treede H; Schlitt A
    Vasc Health Risk Manag; 2019; 15():477-483. PubMed ID: 31802881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality control to improve LDL-cholesterol management in patients with acute coronary syndromes based on the ACS EuroPath IV project.
    Schiele F; Catapano AL; De Caterina R; Laufs U; Jukema JW; Zaman A; Sionis A
    Eur Heart J Acute Cardiovasc Care; 2024 Feb; 13(1):46-54. PubMed ID: 37832522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome.
    Bruckert E; Desamericq G; Khachatryan A; Ngo P; Gusto G; Sorio-Vilela F
    Rev Cardiovasc Med; 2020 Dec; 21(4):643-650. PubMed ID: 33388010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid management across Europe in the real-world setting: a rapid evidence review.
    Barrios V; Soronen J; Carter AM; Anastassopoulou A
    Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.
    Munkhaugen J; Sverre E; Otterstad JE; Peersen K; Gjertsen E; Perk J; Gullestad L; Moum T; Dammen T; Husebye E
    Eur J Prev Cardiol; 2017 Jun; 24(9):981-989. PubMed ID: 28196429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid management and cholesterol goal attainment in Norway.
    Ose L; Skjeldestad FE; Bakken IJ; Levorsen A; Alemao EA; Yin DD; Borgström F; Jönsson L
    Am J Cardiovasc Drugs; 2006; 6(2):121-8. PubMed ID: 16555865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals.
    Khatib R; Yeh EJ; Glowacki N; McGuiness CB; Xie H; Wade RL; Kalich BA; Li Y; Rifai A; Sawlani N
    Clin Epidemiol; 2023; 15():547-557. PubMed ID: 37168051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
    Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.